Hi Andrew,
No problem.
Page 7 of the company's Annual Report highlighted that in addition to the high priority cargo classes, PYC will also look to pursue three additional cargo classes in partnership with third parties as ‘secondary’ priorities. Scaffolds was one of those cargo classes.
https://hotcopper.com.au/threads/ann-annual-report-to-shareholders.4489971/?post_id=36129749
The company also highlighted that they have existing collaborations and MTAs relevant to some of these cargo classes that will yield ‘proof of concept’ results in CY19.The company highlight in presentations that they can deliver biologics into cells with their FPPs. Refer to slide 4 of this presentation below.
https://phylogica.com/wp-content/uploads/2018/01/180109-PYC-Pivot-to-Platform-BioShowcase-Presentation.pdf
If you refer to slide 19 of this presentation below, you will note that the company highlighted that a collaboration with an alternative scaffold company was under discussion.
https://phylogica.com/wp-content/uploads/2017/11/171127_Company-Presentation-AGM-2017.pdf
Slide 17 of this presentation below highlights the company's highly potent cargo delivery. The company delivered conjugated FPPs, protein scaffolds and cytotoxins successfully in vitro in the Janssen partnership and highlighted that they were planning further in vivo tests with scaffolds targeting intracellular targets.
Cetryrins - have a read of this https://academic.oup.com/peds/article/29/12/563/2607335
Here was one of the questions I asked in the Hotcopper submitted questions a while ago....
In the March 2012 video briefing, Dr. Paul Watt highlighted that many antibody companies andscaffold companies are displaying diversity within one structural theme. Is this one of the things thatdistinguishes Phylogica from other companies operating in and targeting the 'undruggable' space? Ifso, are you able to elaborate on this point please?
Refer to answer #5 in the Q&A PDF below for a brief summary.
https://hotcopper.com.au/attachments/hot-copper-qa-phylogica-pdf.1095664/
Tony
Ann: Fourfold Delivery Improvement in a New Lead Candidate, page-48
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $723.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |